Cargando…

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses

Objective A multicenter, double-masked, randomized, placebo-controlled, phase two trial of 88 patients with active, moderate-to-severe Graves’ orbitopathy (GO) has demonstrated a significant and rapid response to teprotumumab, an insulin-like growth factor 1 receptor inhibitory monoclonal antibody,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kahaly, George, Douglas, Raymond, Holt, Robert, Francis-Sedlak, Megan, Perdok, Renee, Sile, Saba, Smith, Terry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552477/ http://dx.doi.org/10.1210/js.2019-SAT-554

Ejemplares similares

OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
por: Kahaly, George J, et al.
Publicado: (2020)

SAT-429 Systemic Safety Analysis of Mycophenolate in Graves’ Orbitopathy
por: Lee, Alan C H, et al.
Publicado: (2020)

OR11-4 Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
por: Douglas, Raymond S, et al.
Publicado: (2022)

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023)

FRI554 Pretibial Myxedema Associated With Hashimoto Thyroiditis Treated With Teprotumumab
por: Marta Niedzialkowska, Ewelina, et al.
Publicado: (2023)

Rapidly Progressive Cognitive Decline and Varicella Zoster Blisters Associated With Teprotumumab in 2 Patients With Graves’ Orbitopathy
por: Hoang, Thanh Duc, et al.
Publicado: (2021)

SAT471 Hearing-Related Adverse Events in Teprotumumab Oncology Clinical Trials
por: Smith, Terry J, et al.
Publicado: (2023)

SAT459 Teprotumumab Pooled Efficacy From The European Study Sites Participating In The Phase 2, OPTIC (Phase 3) And OPTIC-X Pivotal Trials
por: Kahaly, George J, et al.
Publicado: (2023)

PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data
por: Smith, Terry J, et al.
Publicado: (2022)

SAT-424 Assessing Content Validity of the Graves’ Ophthalmopathy Quality of Life Questionnaire (GO-QOL) in the United States
por: Stan, Marius N, et al.
Publicado: (2020)

SAT-606 Graves' Orbitopathy Treated with Kahaly's Protocol: IV High Dose Glucocorticoids
por: Patel, Bijal, et al.
Publicado: (2019)

SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED)
por: Xin, Yan, et al.
Publicado: (2020)

SAT-421 Novel Role of Chloroquine and Hydroxychloroquine in Graves’ Orbitopathy Therapy by Targeting Orbital Fibroblasts
por: Guo, Yan, et al.
Publicado: (2020)

SAT554 Follicular Variant of PTCA Initially Presenting with Widespread Metastases
por: Natividad Bisquera, Nichole Andrea, et al.
Publicado: (2023)

Teprotumumab: a disease modifying treatment for graves’ orbitopathy
por: Ting, Michelle, et al.
Publicado: (2020)

RF35 | PSAT268 Reversal of Graves’ Disease Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy
por: Ugradar, Shoaib, et al.
Publicado: (2022)

RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022)

Role of teprotumumab in the treatment of active moderate-to-severe Graves’ orbitopathy
por: Bartalena, Luigi
Publicado: (2022)

Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021)

SAT-557 Functional Thyrotropin Receptor Antibodies Confirm a Novel Graves' Disease Animal Model
por: Diana, Tanja, et al.
Publicado: (2019)

ODP482 Graves Orbitopathy Secondary to Alemtuzumab Infusion for Multiple Sclerosis
por: Alam, Mustafa, et al.
Publicado: (2022)

A case of Tocilizumab-induced thrombocytopenia in steroid-resistant Graves orbitopathy
por: Cuculescu, Victoria, et al.
Publicado: (2023)

PSAT355 A Case Report Identifying Graves’ Ophthalmopathy in a Myasthenia Gravis Crisis and Response to Teprotumumab
por: Zia, Abdul, et al.
Publicado: (2022)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

ODP502 Nodular Pretibial Myxedema without Graves’ Orbitopathy: A Case Report
por: Veeramachaneni, Ravali, et al.
Publicado: (2022)

PSAT261 Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
por: Holt, Robert J, et al.
Publicado: (2022)

A Unique Presentation of Metastatic Follicular Thyroid Cancer Associated with Hyperthyroidism and an Active Graves’ Orbitopathy
por: Al-Jundi, Mohammad, et al.
Publicado: (2021)

SAT-476 Alemtuzumab Induced Graves Disease
por: Caputi, Rafael C, et al.
Publicado: (2020)

SAT489 Grave’s Disease Secondary To Alemtuzumabuse
por: Gong, Michael Shifeng, et al.
Publicado: (2023)

SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease
por: Douglas, Raymond S, et al.
Publicado: (2023)

SAT-580 Tocilizumab Improvement in a Patient with Corticosteroid Resistant Thyroid Orbitopathy: Report of a Case
por: Coy, Andres, et al.
Publicado: (2019)

SAT-603 Graves' Disease and an Anterior Mediastinal Mass
por: Robbins, D'lorah, et al.
Publicado: (2019)

SAT-592 Amiodarone-Induced Cure Of Graves' Disease
por: Sharma, Eliza, et al.
Publicado: (2019)

SAT-605 Immune Thrombocytopenic Purpura in Graves' disease
por: Sajja, Puspalatha, et al.
Publicado: (2019)

SAT-582 Autoimmune Hepatitis Presenting with Graves Disease
por: Coy, Andres, et al.
Publicado: (2019)

SAT-490 A Case of Unilateral Exophthalmos Due to Thyroid Orbitopathy and Its Association with Chronic Kidney Disease
por: Muammar, Ahmad R, et al.
Publicado: (2020)

FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023)

SAT-428 Sex-Specific Risk Gene of Graves’ Disease
por: Zhao, Shuangxia, et al.
Publicado: (2020)

SAT-459 A Grave Complication: Pulmonary Arterial Hypertension
por: Butt, Wajeeha Saeed, et al.
Publicado: (2020)

SAT-498 Graves’-Associated Takotsubo Cardiomyopathy: An Uncommon Condition
por: Mortensen, Michael, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o3stnb3gcn6ruev84ocjsjolpq